Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans
- PMID: 16960169
- DOI: 10.1093/ajcn/84.3.556
Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans
Abstract
Background: Glucagon-like peptide 1 (GLP-1) is a gut hormone that decreases appetite and promotes satiety. Its role in energy metabolism regulation is still poorly understood.
Objective: The aim of the study was to investigate the relation of fasting plasma GLP-1 concentrations to rates of energy expenditure (EE) and substrate oxidation-ie, respiratory quotient (RQ).
Design: Forty-six glucose-tolerant white subjects (22 men, 24 women) aged 18-49 y whose adiposity spanned a wide range [body mass index (in kg/m2): 18.5-50] were studied in an inpatient clinic. Main outcome measures included resting EE and RQ (ventilated hood technique), body composition (dual-energy X-ray absorptiometry), and fasting plasma concentrations of GLP-1, pancreatic polypeptide, glucose, and insulin.
Results: Fasting plasma GLP-1 concentrations were positively associated with resting EE (after adjustment for age, sex, and body composition) and negatively correlated with RQ (after adjustment for age, sex, and percentage body fat) and fasting plasma pancreatic polypeptide concentrations (both before and after adjustment for age, sex, percentage body fat, and fasting plasma glucose and insulin concentrations). Adjustment for fasting plasma pancreatic polypeptide concentrations, a marker of parasympathetic outflow to the gut, attenuated the strength of the association of fasting plasma GLP-1 concentrations with resting EE and RQ.
Conclusions: Higher fasting plasma GLP-1 concentrations are associated with higher rates of EE and fat oxidation independent of age, sex, and body composition. The autonomic nervous system may have a role in this relation. This effect, along with the established role of GLP-1 in promoting satiety, may further foster its therapeutic potential in the treatment of obesity.
Similar articles
-
Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?J Endocrinol Invest. 2018 Apr;41(4):439-445. doi: 10.1007/s40618-017-0764-1. Epub 2017 Oct 3. J Endocrinol Invest. 2018. PMID: 28975572
-
Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber.Am J Clin Nutr. 2006 Jan;83(1):89-94. doi: 10.1093/ajcn/83.1.89. Am J Clin Nutr. 2006. PMID: 16400055 Clinical Trial.
-
Plasma adiponectin levels are not associated with fat oxidation in humans.Obes Res. 2002 Oct;10(10):1016-20. doi: 10.1038/oby.2002.138. Obes Res. 2002. PMID: 12376582
-
Energy balance, body composition, sedentariness and appetite regulation: pathways to obesity.Clin Sci (Lond). 2016 Sep 1;130(18):1615-28. doi: 10.1042/CS20160006. Clin Sci (Lond). 2016. PMID: 27503946 Review.
-
Long-lasting effects of undernutrition.Int J Environ Res Public Health. 2011 Jun;8(6):1817-46. doi: 10.3390/ijerph8061817. Epub 2011 May 26. Int J Environ Res Public Health. 2011. PMID: 21776204 Free PMC article. Review.
Cited by
-
Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice.PLoS One. 2008 Aug 6;3(8):e2892. doi: 10.1371/journal.pone.0002892. PLoS One. 2008. PMID: 18682834 Free PMC article.
-
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.Ther Adv Chronic Dis. 2018 Jan;9(1):33-50. doi: 10.1177/2040622317735283. Epub 2017 Nov 9. Ther Adv Chronic Dis. 2018. PMID: 29344329 Free PMC article. Review.
-
Is the GLP-1 system a viable therapeutic target for weight reduction?Rev Endocr Metab Disord. 2011 Sep;12(3):187-95. doi: 10.1007/s11154-011-9170-8. Rev Endocr Metab Disord. 2011. PMID: 21336840 Free PMC article. Review.
-
Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor.PLoS One. 2015 May 4;10(5):e0126177. doi: 10.1371/journal.pone.0126177. eCollection 2015. PLoS One. 2015. PMID: 25938560 Free PMC article.
-
Acetate Does Not Affect Palmitate Oxidation and AMPK Phosphorylation in Human Primary Skeletal Muscle Cells.Front Endocrinol (Lausanne). 2021 Jun 17;12:659928. doi: 10.3389/fendo.2021.659928. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34220709 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical